Benzinga · Mar 5, 2026
IC
NASDAQ · ICU
SeaStar Medical Holding Corporation
Healthcare · Biotechnology
$3.18
Up+$0.01 (+0.32%)
Updated Aug 15, 2026, 8:54 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.51M
- P/E ratio
- -0.66
- Dividend yield
- 0.00%
- 52-week range
- $2.07 – $12.50
- Volume
- 58.84K
- Avg. volume
- 2.7M
Price performance
ICU price history
1M range · 21 trading sessions · Daily adjusted prices
ICU closed at $3.18 after 21 trading sessions, down 20.50% for the selected period.
- Last close
- $3.18
- Period change
- -20.50%
- Period low
- $3.02
- Period high
- $4.00
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $3.15 | $3.29 | $3.11 | $3.18 | 58.84K |
| Aug 13, 2026 | $3.20 | $3.27 | $3.04 | $3.17 | 95.71K |
| Aug 12, 2026 | $3.64 | $3.685 | $3.30 | $3.36 | 159.21K |
| Aug 11, 2026 | $3.69 | $3.85 | $3.61 | $3.69 | 98.84K |
| Aug 10, 2026 | $3.30 | $3.815 | $3.30 | $3.69 | 205.19K |
| Aug 7, 2026 | $3.15 | $3.30 | $3.06 | $3.28 | 62.49K |
| Aug 6, 2026 | $3.155 | $3.155 | $3.02 | $3.05 | 47.82K |
| Aug 5, 2026 | $3.225 | $3.245 | $2.96 | $3.02 | 84.56K |
| Aug 4, 2026 | $3.22 | $3.37 | $3.07 | $3.19 | 66.52K |
| Aug 3, 2026 | $3.15 | $3.289 | $3.12 | $3.195 | 46.97K |
| Jul 31, 2026 | $3.33 | $3.33 | $3.06 | $3.13 | 84.7K |
| Jul 30, 2026 | $3.30 | $3.43 | $3.15 | $3.18 | 50.14K |
| Jul 29, 2026 | $3.48 | $3.72 | $3.24 | $3.25 | 61.59K |
| Jul 28, 2026 | $3.51 | $3.53 | $3.40 | $3.44 | 39.87K |
| Jul 27, 2026 | $3.79 | $3.96 | $3.57 | $3.57 | 66.37K |
| Jul 24, 2026 | $3.805 | $3.85 | $3.66 | $3.75 | 78.48K |
| Jul 23, 2026 | $3.90 | $3.95 | $3.6801 | $3.74 | 68.68K |
| Jul 22, 2026 | $3.84 | $4.0399 | $3.80 | $3.89 | 29.99K |
| Jul 21, 2026 | $3.84 | $3.95 | $3.7001 | $3.86 | 51.72K |
| Jul 20, 2026 | $4.07 | $4.11 | $3.8002 | $3.85 | 36.75K |
| Jul 17, 2026 | $4.16 | $4.29 | $3.95 | $4.00 | 77.08K |
Latest ICU news
The latest Smart Investors Daily articles mentioning ICU.
Stock researchCompany · Overview
ICU research
Overview
Company profile and research snapshot.
Company profile
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Maxim Group | Buy | — |
| Apr 20, 2023 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 9, 2026
SeaStar Medical Publishes Data On Early Post-Approval Clinical Experience From Use Of QUELIMMUNE Device For Pediatrics Therapy
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective
Yahoo · Jan 29, 2026
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of SeaStar M
globenewswire.com · Dec 2, 2025
SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI
FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
